Pharmaceutical Industry Articles & Reports

Analyze the FDA AI early-phase clinical trials RFI. This guide covers pilot program objectives, AI evaluation metrics, and evidence-based response strategies.

Review this educational playbook for Veeva CRM Approved Email implementation. Learn about technical setup, compliance frameworks, HCP engagement, and pitfalls.

Examine Phase 2/3 trial results for TAK-881, a 20% SCIG therapy for primary immunodeficiency offering comparable IgG exposure in half the infusion volume.

Examine AI in pharma HEOR and real-world evidence. This report details how machine learning and RWD advance health economic modeling and regulatory decisions.

Review the FDA full approval of Tecartus for relapsed mantle cell lymphoma. This analysis covers ZUMA-2 Cohort 3 efficacy data, CAR-T safety, and clinical use.

Review the Veeva Vault 26R2 release preview. Learn about mid-2026 platform enhancements, including document viewer upgrades, QMS, RIM, and safety workflows.

Analyze the 2026 biotech capital outlook, detailing Blackstone's record $6.3B Life Sciences Fund VI, VC funding trends, biopharma M&A, and market recovery.

Review the 2026 pharma AI vendor landscape. This analysis details 150+ companies using machine learning for drug discovery, clinical trials, and manufacturing.

Analyze the BeOne-Huahui licensing agreement for the HH160 PD-1/CTLA-4/VEGF trispecific antibody. Review recent China biotech cross-border licensing trends.

Examine the FDA approval of Otarmeni, the first gene therapy for OTOF-related congenital hearing loss, and its expedited National Priority Voucher review.

Analyze AcuityMD's $80M Series C funding and the role of AcuityAI. Learn how agentic AI optimizes MedTech commercial operations, sales, and market access.

Analyze how AI clinical trial recruitment addresses enrollment bottlenecks. This report examines Iterative Health's $77M expansion into cardiology and obesity.

Examine the $2.25B Eli Lilly-Profluent deal. Learn how generative AI and protein design are creating novel recombinases for kilobase-scale genome editing.

A 2026 comparison guide of open-source LIMS platforms for life science labs. Learn about system architectures, customizability, and compliance trade-offs.

Examine the 2026 FDA real-time clinical trial pilot. This report analyzes how AI and cloud platforms enable continuous oncology data monitoring for new drugs.

Understand why large language models (LLMs) improve performance when given high-stakes or emotional prompts, and explore research on the EmotionPrompt effect.

Analyze LLM position bias, including primacy and recency effects in transformer models. Learn how prompt structure impacts attention and generation accuracy.

Examine the FDA's first warning letter for AI misuse in cGMP manufacturing. This review details compliance lessons and human oversight requirements for QA.

Examine the impact of Novartis CEO Vas Narasimhan joining Anthropic's board. This report analyzes pharma AI governance, healthcare regulations, and drug R&D.

Review this 2026 vendor comparison of clinical trial payment software. Analyze automated site payment and participant stipend management system capabilities.

Analyze Q1 2026 biopharma M&A trends, including 19 billion-dollar deals. Learn how patent cliffs and AI valuation drivers impact pharmaceutical acquisitions.

Analyze the role of multi-agent AI and co-scientist architectures, including withZeta.ai, in accelerating rare cancer drug discovery and modern oncology R&D.

Review AI molecule prioritization methods and computational triage tools used in drug discovery pipelines to filter generative AI candidates via ADMET and QSAR.

Read a comprehensive analysis of Veeva's Ostro acquisition. Learn how conversational AI integrates with Vault CRM for MLR-compliant HCP and patient engagement.